<DOC>
	<DOCNO>NCT02550652</DOCNO>
	<brief_summary>This Phase II study compare efficacy safety obinutuzumab plus mycophenolate mofetil ( MMF ) /mycophenolic acid ( MPA ) placebo plus MMF/MPA participant proliferative LN .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Obinutuzumab Compared With Placebo Participants With Lupus Nephritis ( LN )</brief_title>
	<detailed_description />
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Diagnosis Systemic Lupus Erythematosus ( SLE ) , accord current American College Rheumatology ( ACR ) criteria Diagnosis International Society Nephrology/Renal Pathology Society ( ISN/RPS ) 2003 Class III IV LN evidence renal biopsy perform within 6 month prior screen . Participants may coexhibit Class V disease addition either Class III Class IV disease Proteinuria ( urine protein creatinine ratio ) great ( &gt; ) 1.0 For woman postmenopausal ( great equal [ &gt; /= ] 12 month nontherapyinduced amenorrhea ) surgically sterile ( absence ovary and/or uterus ) : agreement remain abstinent use two adequate method contraception , include least one method failure rate le ( &lt; ) 1 percent ( % ) per year , treatment period least 18 month last dose study drug For men : agreement remain abstinent use condom plus additional contraceptive method together result failure rate &lt; 1 % per year treatment period least 12 month last dose study drug agreement refrain donate sperm period Retinitis , poorly control seizure disorder , acute confusional state , myelitis , stroke stroke syndrome , cerebellar ataxia , dementia currently active result SLE Presence rapidly progressive glomerulonephritis Severe renal impairment define estimate Glomerular Filtration Rate ( GFR ) &lt; 30 milliliter per minute ( mL/min ) need dialysis renal transplant Greater 50 % glomeruli sclerosis renal biopsy Treatment cyclophosphamide calcineurin inhibitor within 3 month prior randomization Unstable disease thrombocytopenia high risk develop clinically significant bleed organ dysfunction require therapy plasmapheresis acute blood platelet transfusion History severe allergic anaphylactic reaction monoclonal antibody know hypersensitivity component obinutuzumab infusion Significant uncontrolled medical disease organ system related SLE LN , , investigator 's opinion , would preclude participant participation Concomitant chronic condition , exclude SLE , ( e.g. , asthma , Crohn 's disease ) require oral systemic steroid use 52 week prior screen Previous treatment anticluster differentiation ( CD20 ) target therapy within 12 month Previous treatment biologic Bcelltargeted therapy ( antiCD20 ) within 6 month randomization Known intolerance MMF MPA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>